Copenhagen Research Center for Mental Health-CORE, Mental Health Center Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark.
Section of Epidemiology, Department of Public Health, University of Copenhagen, Copenhagen, Denmark.
JAMA Psychiatry. 2021 Sep 1;78(9):1013-1019. doi: 10.1001/jamapsychiatry.2021.1471.
Cannabis use and potency of cannabis have increased during the past 2 decades. If the association between cannabis use and schizophrenia is causal, this should be reflected in an increase in the proportion of cases of schizophrenia being attributable to cannabis, the population-attributable risk fraction (PARF).
To determine whether the PARF for cannabis use disorder in schizophrenia has increased over time.
DESIGN, SETTING, AND PARTICIPANTS: This nationwide, register-based historical prospective cohort study included all people in Denmark born before December 31, 2000, who were alive and 16 years or older at some point from January 1, 1972, to December 31, 2016. Data analysis was performed from August 2020 to April 2021.
Diagnosis of cannabis use disorder.
Diagnosis of schizophrenia, with estimated PARF of cannabis use disorder in schizophrenia from 1972 to 2016.
A total of 7 186 834 individuals were included in the analysis, including 3 595 910 women (50.0%) and 3 590 924 men (50.0%). The adjusted hazard ratio for schizophrenia fluctuated at approximately 4 (with 95% CIs ranging from approximately 3 to 6) throughout most of the study period when people diagnosed with cannabis use disorder were compared with those without cannabis use disorder. The PARF of cannabis use disorder in schizophrenia also fluctuated, but with clear evidence of an increase from 1995 (when the PARF was relatively stable around 2.0%, with a 95% CI of approximately 0.3% to either side) until reaching some stability around 6.0% to 8.0% (with a 95% CI of approximately 0.5% to either side) since 2010.
The results from these longitudinal analyses show the proportion of cases of schizophrenia associated with cannabis use disorder has increased 3- to 4-fold during the past 2 decades, which is expected given previously described increases in the use and potency of cannabis. This finding has important ramifications regarding legalization and control of use of cannabis.
在过去的 20 年中,大麻的使用和效力都有所增加。如果大麻使用与精神分裂症之间存在因果关系,那么这应该反映在归因于大麻的精神分裂症病例比例(PARF)增加上。
确定精神分裂症中与大麻使用障碍相关的 PARF 是否随时间推移而增加。
设计、设置和参与者:这是一项全国范围内基于登记的历史前瞻性队列研究,纳入了所有于 1972 年 12 月 31 日前出生、在 1972 年 1 月 1 日至 2016 年 12 月 31 日期间的某个时间点存活且年满 16 岁的丹麦人。数据分析于 2020 年 8 月至 2021 年 4 月进行。
大麻使用障碍的诊断。
精神分裂症的诊断,估计 1972 年至 2016 年精神分裂症中与大麻使用障碍相关的 PARF。
共纳入 7186834 人进行分析,其中包括 3595910 名女性(50.0%)和 3590924 名男性(50.0%)。与未患有大麻使用障碍的人相比,患有大麻使用障碍的人在研究期间的大部分时间内,精神分裂症的调整后危险比波动在 4 左右(95%CI 范围为 3 到 6)。与大麻使用障碍相关的精神分裂症的 PARF 也在波动,但自 2010 年以来,有明确证据表明其从 1995 年开始增加(当时 PARF 相对稳定在 2.0%左右,95%CI 大约在 0.3%到两侧),直到达到 6.0%到 8.0%左右(95%CI 大约在 0.5%到两侧)的某种稳定状态。
这些纵向分析的结果表明,在过去的 20 年中,与大麻使用障碍相关的精神分裂症病例比例增加了 3 到 4 倍,这与大麻使用和效力的增加是一致的。这一发现对大麻的合法化和使用控制具有重要意义。